Treatment of SÅ«â??al-Qinya (low hemoglobin level in blood) with Unani medicine Qurs-e-Zarishk

An open-label, Clinical Validation Study to Evaluate the Efficacy and Safety of Unani Pharmacopoeial formulation â?? Qurs-e-Zarishk in SÅ«â??al-Qinya (Anemia)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/12/038795

Enrollment

110

Registered

2021-12-21

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D500- Iron deficiency anemia secondary to blood loss (chronic)

Interventions

Intervention1: Qurs-e-Zarishk: Majoon-e- Ushba 2tablets Thrice daily Orally with water for 12 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hb% 8 gm/dl 2. Female patients in the age group of 18-65 years 3. With or without following complaints: Fatigue General weakness Dizziness Palpitation Breathlessness Restless leg syndrome Thumping or whooshing sound in ear Loss of appetite Chest pain Fainting

Exclusion criteria

Exclusion criteria: 1. Concomitant medications or history of blood transfusion within prior to 120 days. 2. Known case of any severesystemic diseases such as allergic asthma, chronic kidney diseases, auto-immune disorders(SLE, RA, ulcerative colitis), heart diseases and canceretc. 3. Known cases of any other acute illness. 4. Known case ofhemogolobinopathy or other red celldisordersThalassemias, sickle cell anemia, congenital dyserythropoietic anemia etc. 5. History of hypersensitivity to the investigational drug or herbal drugs. 6. Pregnant and nursing women.

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of SÅ«â??al-Qinya (Anemia)Timepoint: 12weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026